Complications after CD19+ CAR T-Cell Therapy

SIMPLE SUMMARY: CD19+ Chimeric antigen receptor (CAR) T-cells are used against CD19+ hematologic malignancies, such as high-grade B-cell lymphoma and acute lymphoblastic leukemia. Since this is a relatively new treatment approach, not all potential side effects are well described, and the underlying...

Descripción completa

Detalles Bibliográficos
Autores principales: Penack, Olaf, Koenecke, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7699604/
https://www.ncbi.nlm.nih.gov/pubmed/33228221
http://dx.doi.org/10.3390/cancers12113445

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7699604/
https://www.ncbi.nlm.nih.gov/pubmed/33228221
http://dx.doi.org/10.3390/cancers12113445

Ejemplares similares